Sample Data Abstract Forms

Katherine E Hartmann; Melissa L McPheeters; Daniel H Biller; Renée M Ward; J Nikki McKoy; Rebecca N Jerome; Sandra R Micucci; Laura Meints; Jill A Fisher; Theresa A Scott; James C Slaughter; Jeffrey D Blume

This publication is provided for historical reference only and the information may be out of date.

Appendix BSample Data Abstract Forms

Publication Details

Systematic Review of the Etiology and Treatment of Overactive Bladder in Women

Abstract Review Form

First Author, Year: _________

Reference #_________ Abstractor Initials: ___ ___ ___

Table

___Not OAB (including post-operative/iatrogenic) ___Stress or mixed incontinence

OAB is operationalized as idiopathic urinary urgency and frequency

Retain for:

____BACKGROUND/DISCUSSION

____REVIEW OF REFERENCES

____Other__________

COMMENTS:

Systematic Review of the Treatment Alternatives of Overactive Bladder in Women

Full-text Review Form

First Author, Year: __________

Reference #__________

Abstractor Initials: ___ ___ ___

OAB is operationalized as idiopathic urinary urgency and frequency

Table

___Not OAB (including post-operative/iatrogenic) ___Stress or mixed incontinence

EXCLUDE IF AN ITEM IN A GRAY BOX IS SELECTED

Table

___Pharmacologic ___Surgical

Retain for:

____BACKGROUND/DISCUSSION

____REVIEW OF REFERENCES

____Other__________

COMMENTS:

Publication Details

Copyright

Publisher

Agency for Healthcare Research and Quality (US), Rockville (MD)

NLM Citation

Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of Overactive Bladder in Women. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Aug. (Evidence Reports/Technology Assessments, No. 187.) Appendix B, Sample Data Abstract Forms.

Primary Inclusion/Exclusion Criteria
1. Applies to SER topic (If not, select at least one of the following reasons): ___Not OAB (including post-operative/iatrogenic) ___Stress or mixed incontinence ___Isolated nocturia ___Interstitial cystitis/painful bladder syndrome ___Pelvic organ prolapse ___Neurogenic conditions ___Basic science or anatomy only ___Imaging/diagnostic study only ___Other__________	Yes	No	Cannot Determine
2. Original research (exclude editorials, commentaries, letters to editor, reviews, etc)	Yes	No	Cannot Determine
3. Study published in English	Yes	No
4. Adult female study population (or includes women)	Yes	No	Cannot Determine
5. Ambulatory population (exclude if exclusively institutionalized or home-bound)	Yes	No
6. Eligible Study type ___RCT ___Cohorts with comparison ___Case-control ___Case series ___Incidence/prevalence in representative populations ___Cost of treatment in US populations (monetary & non-monetary)	Yes	No	Cannot Determine
7. Eligible study size Record N if < 50 relevant subjects enrolled: __________	Yes	No	Cannot Determine

Primary Inclusion/Exclusion Criteria
8. Applies to SER topic (If not, select at least one of the following reasons): ___Not OAB (including post-operative/iatrogenic) ___Stress or mixed incontinence ___Isolated nocturia ___Interstitial cystitis/painful bladder syndrome ___Pelvic organ prolapse ___Neurogenic conditions ___Basic science or anatomy only ___Imaging/diagnostic study only ___Other__________	Yes	No
9. Original research (exclude editorials, commentaries, letters to editor, reviews, etc)	Yes	No
10. Study published in English	Yes	No
11. Adult female study population (or reports data by gender) If No, % female__________	Yes	No
12. Ambulatory population (exclude if exclusively institutionalized or home-bound)	Yes	No
13. Eligible Study type g. ___RCT /CCT h. ___Cohorts with comparison i. ___Case-control j. ___Case series k. ___Incidence/Prevalence study (survey-based) l. ___Cost benefit/utility/effectiveness study	Yes	No
14. Eligible study size Record N if < 50 relevant subjects enrolled: __________	Yes	No
15. Does study address one of the following: ___Treatment of OAB ___Incidence/prevalence of OAB ___Monetary costs of treatment ___Non-monetary costs/harms of treatment	Yes	No

Content Inventory

1. ___Treatment of women with symptoms of OAB

___Pharmacologic
___Surgical
1. ___Botox
2. ___Central neuromodulation
  ___Sacral
3. ___Peripheral neuromodulation
  ___Tibial
  ___Pudendal
4. ___Augmentation cystoplasty
5. ___Other__________
___Behavioral/Physical Therapy
___Complementary and alternative therapies
___Other__________

2. Modification of outcomes by:

___Age
___Body habitus/BMI
___Clinical presentation, physical exam findings, urodynamic findings, symptom cluster
___Diabetes
___Functional status
___Hormone replacement therapy
___Menopausal status
___Parity/post-partum/route-of-delivery
___Prior treatment
___Race/ethnicity
___Smoking
___Hysterectomy
___Other factors__________

Length of follow-up:__________